Is The Door Opening For Chinese investment In Bay Area Biotechs?

Eureka Therapeutics Inc. wasn't looking for Chinese investors specifically, but — especially in the cash-intensive biotech industry — you don't look gift yuan in the mouth. About six months after the initial inquiry to the Emeryville cancer-fighting antibody developer, Eureka completed a $21 million Series C round led by Chinese private equity firm Yuan Capital. About half of the round was tendered by Chinese investors.